Raybow USA supported the synthetic process for Sophrosyne Pharmaceuticals’ Preclinical Research on Alcohol Use Disorder Therapy preclinical data for SOPH-110S, as published in the peer reviewed journal, Cells. The article is entitled “A Novel ALDH2 Inhibitor for the Treatment of Alcohol Use Disorder: Preclinical Findings.”

The research findings supported FDA IND clearance and initiation of their Phase 1 study on Alcohol Use Disorder—an important step forward in the progress of transforming brain health therapeutics.

Raybow USA performed the initial racemic synthesis of SOPH-110. The chiral separation was performed under Raybow’s GMP protocol (Lotus Separations LLC, Princeton, NJ, USA) and produced >98% chemical purity and >99% chiral purity.

Yue Ning “Nathan” Jiao, PhD, Group Leader for Raybow USA, reflected on the multiple levels of the project’s impact.

“It is a great personal privilege to be part of this mission to develop an effective treatment for alcohol use disorder.

“Our ADD: Raybow and Sophrosyne teams’?? rigorous, result-focused research and development lays the foundation of robust, replicable protocols that drive real advance public health, bringing change to individuals and communities worldwide.

“It has been a genuine pleasure collaborating with Sophrosyne Pharmaceutical on this project, and together we’ve accomplished so much. Creativity and shared goals make project development a delight.”

Link to the full article here: https://res.cloudinary.com/drw/image/upload/v1768931660/comm-sophrosyne/pdfs/Marshall_Fowlie_Sabouni_Cells_2026_ALDH2_inhibitor_for_AUD_preclinical_findngs_tfcgoc.pdf.

Connect with Raybow USA for support with your integrated small-molecule CMC discovery, IND-enabling studies, and GMP manufacturing.

About Raybow USA

Founded in 1998 as PharmAgra Labs by Peter Newsome and Roger Frisbee, the Brevard, North Carolina, company became Raybow USA, a US branch of JiuZhou Pharma in 2019.

The facility is dedicated to cutting-edge Research & Development and Analytical services, offering preparation of clinical trial material, method validation, and small-scale specialty manufacturing for multiple markets. The FDA-inspected site boasts a cGMP laboratory and kilo lab.

About JiuZhou Pharma

Zhejiang JiuZhou Pharmaceutical Co., LTD. (stock code: 603456.SH), founded in 1998 and headquartered in Taizhou, Zhejiang, is a leading CDMO and generic drug manufacturer in China. The company has production and R&D bases in China, Germany, Japan, and the United States.

JiuZhou Pharma provides full-lifecycle contract development and manufacturing services to pharmaceutical companies worldwide. The one-stop CDMO service spans from preclinical research, process R&D for APIs, DPs, peptides, and drug conjugates, through all clinical phases to commercial production.

#syntheticchemistry #analyticalchemistry #pharmaceuticals #specialtychemicals #cdmo #pharmaceuticalresearchanddevelopment #methoddevelopment #gmp #smallmolecule

###